search results for 
Logo

Sales and earnings by business segment

In 2013, we expect further increases in sales and a healthy earnings development in each of our business segments. The table gives an overview.

FINANCIAL TARGETS BY BUSINESS SEGMENT


  Targets 2013 Fiscal year 2012
1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA, 2012 before special items 2 Sales 3 EBIT
Fresenius Medical Care    
Sales > US$14.6 bn US$13,800 bn
Net income1 US$1.1 bn – US$1.2 bn US$1,118 bn
Fresenius Kabi    
Sales growth (in constant currency) 12% – 14% 10%
Sales growth (organic) 3% – 5% €4,539 m2
EBIT margin excl. Fenwal 19% – 20% 20.6%
EBIT margin incl. Fenwal 18% – 19%  
Fresenius Helios    
Sales growth (organic) 3% – 5% €3,200 m2
EBIT €360 m – €380 m €322 m
Fresenius Vamed    
Sales growth 8% – 12% 846 m2
EBIT growth 5% – 10% €51 m3

  Targets 2013 Fiscal year 2012
1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA, 2012 before special items 2 Sales 3 EBIT
Fresenius Medical Care    
Sales > US$14.6 bn US$13,800 bn
Net income1 US$1.1 bn – US$1.2 bn US$1,118 bn
Fresenius Kabi    
Sales growth (in constant currency) 12% – 14% 10%
Sales growth (organic) 3% – 5% €4,539 m2
EBIT margin excl. Fenwal 19% – 20% 20.6%
EBIT margin incl. Fenwal 18% – 19%  
Fresenius Helios    
Sales growth (organic) 3% – 5% €3,200 m2
EBIT €360 m – €380 m €322 m
Fresenius Vamed    
Sales growth 8% – 12% 846 m2
EBIT growth 5% – 10% €51 m3

The number of dialysis patients worldwide should rise by about 6% again in 2013, leading to continued growth in demand for dialysis products and a higher number of treatments. For 2013, Fresenius Medical Care expects sales to grow to more than US$14.6 billion. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between US$1.1 billion and US$1.2 billion.

Fresenius Kabi reported strong full-year results. Despite the high base, Fresenius Kabi expects its positive operating performance to continue. In 2013, Fresenius Kabi expects further significant growth supported by the full-year consolidation of Fenwal and continued organic growth in emerging markets and Europe. In North America, we expect the IV drug supply constraints to alleviate and competitors to re-enter the U.S. market for Propofol. Fresenius Kabi has been sole supplier for Propofol in the United States since the end of March 2012. For 2013, Fresenius Kabi projects sales growth of 12% to 14% in constant currency. Organic sales growth is expected in the range of 3% to 5%. The company projects an EBIT margin of 19% to 20% excluding Fenwal and of 18% to 19% including Fenwal. EBIT in constant currency is expected to exceed 2012 EBIT. The guidance includes expected one-time charges to remediate manufacturing issues following recent FDA audits at the Grand Island, USA, and Kalyani, India, facilities. It also includes a gain related to the sale of the respiratory homecare business in France. The Fresenius Kabi guidance is adjusted for one-time integration costs of Fenwal, Inc. (~€50 million pre tax).

For the mid-term, Fresenius Kabi targets annual organic sales growth of 7% to 10% and an EBIT margin in the range of 18% to 21%. By 2015, the company expects sales to reach approx. €6 billion and EBIT to reach more than €1.1 billion.

Fresenius Helios expects to continue its excellent performance in the hospital operations business. For 2013, Fresenius Helios expects to achieve organic sales growth of 3% to 5%. EBIT is projected to increase to between €360 million and €380 million.

Fresenius Helios targets sales of €4 billion to €4.25 billion by 2015, driven by organic growth and acquisitions.

Given its excellent order backlog of €987 million and long-term agreements in its services business, Fresenius Vamed has an excellent base for further growth. In 2013, Fresenius Vamed expects to achieve sales growth of 8% to 12%. EBIT is projected to increase by 5% to 10%.

Fresenius Vamed targets sales of €1 billion by 2014.

Continue reading:
Financing

QUICKFINDER

History

Tools